Cell Cycle Progression Stimulated by Tamoxifen-Bound Estrogen Receptor-α and Promoter-Specific Effects in Breast Cancer Cells Deficient in N-CoR and SMRT
Erika Krasnickas Keeton(Dana-Farber Cancer Institute), Myles Brown(Harvard University)
Cited by 103
Related Papers
Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2025|2
Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination–proficient prostate cancer
|Proceedings of the National Academy of Sciences|2026|2